Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Intuitive Surgical Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Dividend Discount Model (DDM)
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Intuitive Surgical Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The liquidity profile exhibits a consistently strong position, characterized by high margins of safety across all measured ratios from March 2022 through March 2026. A recurring seasonal pattern is observed, where liquidity metrics typically experience a contraction in the fourth quarter of each calendar year, followed by a recovery in the first quarter of the subsequent year.
- Current Ratio
- The current ratio remained robust throughout the period, fluctuating between a high of 5.55 in March 2024 and a low of 4.07 in December 2024. While there is a slight downward trajectory in the troughs since 2022, the ratio consistently stayed above 4.0, indicating a substantial capacity to cover short-term obligations with current assets.
- Quick Ratio
- The quick ratio followed a trend closely aligned with the current ratio, peaking at 4.49 in June 2022 and reaching a period low of 3.00 in December 2024. The narrow spread between the current and quick ratios suggests that inventory levels do not represent a disproportionate share of current assets, ensuring that liquidity is not heavily reliant on the sale of physical stock.
- Cash Ratio
- The cash ratio maintained high levels, ranging from a peak of 3.86 in September 2023 to a minimum of 2.30 in December 2024. The fact that this ratio remained well above 2.0 throughout the entire analyzed timeframe indicates an exceptional level of immediate solvency, with cash and cash equivalents alone being sufficient to cover current liabilities multiple times over.
Overall, a gradual decline in peak liquidity values is observable between 2023 and 2026, particularly within the quick and cash ratios. Despite this moderation, the overall liquidity position remains highly conservative, providing significant financial flexibility and a minimal risk of short-term insolvency.
Current Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Current assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity position remains exceptionally robust across the analyzed period, characterized by a significant surplus of current assets relative to current liabilities. The current ratio consistently operates at levels well above the conventional industry benchmark of 1.0, indicating a substantial capacity to meet short-term financial obligations.
- Current Assets Trend
- A general upward trajectory in current assets is observed, rising from $5.8 billion in March 2022 to a peak of approximately $9.78 billion in December 2025. Although some volatility occurred, particularly during 2024, the overall trend reflects a significant accumulation of short-term resources over the period.
- Current Liabilities Progression
- Current liabilities exhibited a steady increase, growing from $1.11 billion in March 2022 to $1.91 billion by March 2026. This growth in short-term obligations was gradual and remained well-supported by the corresponding growth in assets, preventing any critical degradation of liquidity.
- Current Ratio Analysis
- The current ratio fluctuated between a high of 5.55 in March 2024 and a low of 4.07 in December 2024. A recurring pattern is evident where liquidity ratios often peak in the first quarter of the year and experience a contraction toward the fourth quarter. Despite these fluctuations, the ratio consistently remained above 4.0, signaling a highly conservative liquidity posture and a significant safety margin for the organization.
Quick Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The analysis of the liquidity position indicates a consistently strong ability to cover short-term obligations, although a gradual contraction in the quick ratio is evident over the observed period. While the ratio remains well above the standard threshold of 1.0, there is a noticeable shift in the balance between quick assets and current liabilities.
- Quick Asset Dynamics
- Total quick assets exhibited significant volatility, peaking at approximately 7.44 billion USD in September 2023 and again in December 2025. A period of contraction was observed between September 2023 and December 2024, during which assets declined from 7.44 billion USD to 5.24 billion USD before returning to a growth phase in 2025.
- Current Liability Trends
- A steady upward trajectory is observed in current liabilities, which increased from 1.11 billion USD in March 2022 to 1.91 billion USD by March 2026. This consistent growth in short-term obligations serves as a primary driver for the compression of the liquidity ratio over time.
- Quick Ratio Evolution
- The quick ratio transitioned from a high-stability phase between March 2022 and September 2023, where it remained predominantly above 4.0 and peaked at 4.44. Starting in 2024, a downward trend became more pronounced, with the ratio reaching a minimum of 3.00 in December 2024. The period concluded with a ratio of 3.20 in March 2026, suggesting that although the liquidity cushion remains substantial, it has diminished compared to the levels maintained in the early part of the analysis period.
Cash Ratio
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||||
| Short-term investments | |||||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The liquidity position is characterized by a substantial cash reserve relative to short-term obligations, although a gradual decline in the cash ratio is evident over the analyzed period.
- Cash Asset Volatility
- Total cash assets exhibited significant fluctuation, starting at 3.98 billion USD in March 2022 and reaching a peak of 6.47 billion USD in September 2023. A subsequent contraction occurred, with assets declining to a low of 4.01 billion USD by December 2024. While a recovery was observed during 2025, peaking at 5.93 billion USD in December, the balance ended at 4.51 billion USD in March 2026.
- Current Liabilities Growth
- Current liabilities demonstrate a consistent and steady upward trajectory. Obligations increased from 1.11 billion USD in March 2022 to 1.91 billion USD by March 2026. This sustained increase in short-term liabilities has acted as a primary driver in the compression of the liquidity ratio.
- Cash Ratio Trends
- The cash ratio remained well above 2.0 throughout the entire period, indicating a very strong ability to meet immediate financial obligations using only the most liquid assets. The ratio reached its maximum of 3.86 in September 2023, coinciding with the peak in cash assets. Following this peak, a general downward trend emerged, with the ratio settling at 2.36 by March 2026. This decline reflects a shift from an exceptionally high liquidity surplus toward a more moderate, though still robust, solvency level.